Loading...
XASE
XTNT
Market cap91mUSD
Jul 11, Last price  
0.66USD
1D
-4.87%
1Q
60.93%
Jan 2017
-90.08%
IPO
-97.98%
Name

Xtant Medical Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
0.78
EPS
Div Yield, %
Shrs. gr., 5y
58.97%
Rev. gr., 5y
12.64%
Revenues
117m
+28.44%
459,2297,393,49315,417,64730,149,48232,979,89933,073,41435,331,81259,345,71790,002,73682,612,10172,203,00064,682,00053,337,00055,263,00057,969,00091,303,000117,267,000
Net income
-16m
L
-15,845-4,125,742-19,467,922-3,006,469-7,713,822-12,693,125-10,507,869-2,174,430-19,493,552-52,411,262-70,099,000-8,221,000-7,023,000-5,844,000-8,485,000660,000-16,449,000
CFO
-12m
L+25.02%
38,644-3,671,596-8,371,968-7,362,138-10,792,332-5,620,924-7,324,059-9,099,868-14,407,296-543,1801,212,000-413,000-731,000439,000-5,341,000-9,515,000-11,896,000
Earnings
Aug 06, 2025

Profile

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
IPO date
Jun 30, 2010
Employees
134
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
117,267
28.44%
91,303
57.50%
57,969
4.90%
Cost of revenue
129,341
101,461
64,724
Unusual Expense (Income)
NOPBT
(12,074)
(10,158)
(6,755)
NOPBT Margin
Operating Taxes
187
(1,697)
69
Tax Rate
NOPAT
(12,261)
(8,461)
(6,824)
Net income
(16,449)
-2,592.27%
660
-107.78%
(8,485)
45.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,456
14,011
9,311
BB yield
-7.53%
-9.78%
-14.99%
Debt
Debt current
13,664
6,412
6,232
Long-term debt
1,245
19,812
12,513
Deferred revenue
Other long-term liabilities
21,991
210
Net debt
8,710
20,509
(1,553)
Cash flow
Cash from operating activities
(11,896)
(9,515)
(5,341)
CAPEX
(4,113)
(1,456)
(1,764)
Cash from investing activities
(3,730)
(24,784)
(1,559)
Cash from financing activities
16,073
19,691
9,020
FCF
(16,430)
(34,262)
(8,221)
Balance
Cash
6,199
5,715
20,298
Long term investments
Excess cash
336
1,150
17,400
Stockholders' equity
(259,775)
(242,981)
(243,670)
Invested Capital
338,653
318,994
294,913
ROIC
ROCE
EV
Common stock shares outstanding
133,665
126,793
94,085
Price
0.44
-60.80%
1.13
71.21%
0.66
17.86%
Market cap
59,214
-58.67%
143,276
130.73%
62,096
29.76%
EV
67,924
163,785
60,543
EBITDA
(7,850)
(6,984)
(5,463)
EV/EBITDA
Interest
4,160
2,938
1,692
Interest/NOPBT